27392483|t|Liver - specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment
27392483|a|Recently, direct antiviral agents against hepatitis C virus (HCV) infection have been developed as highly effective anti-HCV drugs. However, the appearance of resistant viruses against direct anti-viral agents is an unsolved problem. One of the strategies considered to suppress the emergence of the drug-resistant viruses is to use drugs inhibiting the host factor, which contributes to HCV proliferation, in combination with direct anti-viral agents. The replication complex was reported to be present in the membranous compartment in the cells. Thus, lipid metabolism modulators are good candidates to regulate virus assembly and HCV replication. Recent studies have shown that stearoyl-CoA desaturase (SCD), an enzyme for long-chain mono-unsaturated fatty acid (LCMUFA) synthesis, is a key factor that defines HCV replication efficiency. Systemic exposure to SCD-1 inhibor induces some side effects in the eyes and skin. Thus, systemic SCD-1 inhibitors are considered inappropriate for HCV therapy. To avoid the side effects of systemic SCD-1 inhibitors, the liver - specific SCD-1 inhibitor, MK8245, was synthesized; it showed antidiabetic effects in diabetic model mice with no side effects. In the phase 1 clinical study on measurement of MK8245 tolerability, no significant side effects were reported (ClinicalTrials.gov Identifier: NCT00790556). Therefore, we thought liver - specific SCD-1 inhibitors would be suitable agents for HCV - infected patients. MK8245 was evaluated using recombinant HCV culture systems. Considering current HCV treatments, to avoid the emergence of direct anti-viral agents - resistant viruses, combination therapy with direct anti-viral agents and host - targeted agents would be optimal. With this viewpoint, we confirmed MK8245 's additive or synergistic anti-HCV effects on current direct anti-viral agents and interferon-alpha therapy. The results suggest that MK8245 is an option for anti-HCV multi-drug therapy with a low risk of emergence of drug-resistant HCV without significant side effects.
27392483	0	5	Liver	T017	UMLS:C0023884
27392483	17	55	mono-unsaturated fatty acid synthase-1	T103	UMLS:C0015683
27392483	56	65	inhibitor	T103	UMLS:C0014432
27392483	70	86	anti-hepatitis C	T033	UMLS:C0243095
27392483	87	96	treatment	T058	UMLS:C0087111
27392483	114	130	antiviral agents	T103	UMLS:C0003451
27392483	139	172	hepatitis C virus (HCV) infection	T038	UMLS:C4288963
27392483	266	273	viruses	T005	UMLS:C0042776
27392483	289	306	anti-viral agents	T103	UMLS:C0003451
27392483	322	329	problem	T033	UMLS:C0033213
27392483	397	411	drug-resistant	T038	UMLS:C0013203
27392483	412	419	viruses	T005	UMLS:C0042776
27392483	430	435	drugs	T103	UMLS:C1254351
27392483	485	488	HCV	T005	UMLS:C0220847
27392483	531	548	anti-viral agents	T103	UMLS:C0003451
27392483	554	573	replication complex	T017	UMLS:C1167179
27392483	593	600	present	T033	UMLS:C0150312
27392483	619	630	compartment	T082	UMLS:C1948049
27392483	638	643	cells	T017	UMLS:C0007634
27392483	651	667	lipid metabolism	T038	UMLS:C0598783
27392483	668	678	modulators	T103	UMLS:C1254351
27392483	711	725	virus assembly	T038	UMLS:C0282629
27392483	730	733	HCV	T005	UMLS:C0220847
27392483	734	745	replication	T038	UMLS:C0042774
27392483	778	801	stearoyl-CoA desaturase	T103	UMLS:C0038233
27392483	803	806	SCD	T103	UMLS:C0038233
27392483	812	818	enzyme	T103	UMLS:C0014442
27392483	823	861	long-chain mono-unsaturated fatty acid	T103	UMLS:C0015687
27392483	863	869	LCMUFA	T103	UMLS:C0015687
27392483	871	880	synthesis	T038	UMLS:C0220781
27392483	911	914	HCV	T005	UMLS:C0220847
27392483	915	926	replication	T038	UMLS:C0042774
27392483	960	965	SCD-1	T103	UMLS:C0038233
27392483	966	973	inhibor	T103	UMLS:C0014432
27392483	987	999	side effects	T038	UMLS:C0041755
27392483	1007	1011	eyes	T017	UMLS:C0015392
27392483	1016	1020	skin	T022	UMLS:C1123023
27392483	1037	1042	SCD-1	T103	UMLS:C0038233
27392483	1043	1053	inhibitors	T103	UMLS:C0014432
27392483	1087	1090	HCV	T038	UMLS:C4288963
27392483	1113	1125	side effects	T038	UMLS:C0041755
27392483	1138	1143	SCD-1	T103	UMLS:C0038233
27392483	1144	1154	inhibitors	T103	UMLS:C0014432
27392483	1160	1165	liver	T017	UMLS:C0023884
27392483	1177	1182	SCD-1	T103	UMLS:C0038233
27392483	1183	1192	inhibitor	T103	UMLS:C0014432
27392483	1194	1200	MK8245	T103	UMLS:C3252063
27392483	1229	1249	antidiabetic effects	T033	UMLS:C0243095
27392483	1253	1261	diabetic	T033	UMLS:C0241863
27392483	1262	1272	model mice	T204	UMLS:C0025929
27392483	1278	1280	no	T033	UMLS:C1513916
27392483	1281	1293	side effects	T038	UMLS:C0041755
27392483	1310	1324	clinical study	T062	UMLS:C0008972
27392483	1343	1349	MK8245	T103	UMLS:C3252063
27392483	1350	1362	tolerability	T062	UMLS:C3274448
27392483	1364	1378	no significant	T033	UMLS:C1273937
27392483	1379	1391	side effects	T038	UMLS:C0041755
27392483	1407	1425	ClinicalTrials.gov	T170	UMLS:C4086204
27392483	1474	1479	liver	T017	UMLS:C0023884
27392483	1491	1496	SCD-1	T103	UMLS:C0038233
27392483	1497	1507	inhibitors	T103	UMLS:C0014432
27392483	1526	1532	agents	T103	UMLS:C1254351
27392483	1537	1540	HCV	T005	UMLS:C0220847
27392483	1543	1551	infected	T033	UMLS:C0439663
27392483	1562	1568	MK8245	T103	UMLS:C3252063
27392483	1605	1620	culture systems	T062	UMLS:C1516329
27392483	1642	1645	HCV	T005	UMLS:C0220847
27392483	1646	1656	treatments	T058	UMLS:C0087111
27392483	1691	1708	anti-viral agents	T103	UMLS:C0003451
27392483	1721	1728	viruses	T005	UMLS:C0042776
27392483	1730	1749	combination therapy	T058	UMLS:C0009429
27392483	1762	1779	anti-viral agents	T103	UMLS:C0003451
27392483	1800	1806	agents	T103	UMLS:C1254351
27392483	1859	1865	MK8245	T103	UMLS:C3252063
27392483	1893	1909	anti-HCV effects	T033	UMLS:C0243095
27392483	1928	1945	anti-viral agents	T103	UMLS:C0003451
27392483	1950	1974	interferon-alpha therapy	T058	UMLS:C0854621
27392483	2001	2007	MK8245	T103	UMLS:C3252063
27392483	2025	2033	anti-HCV	T033	UMLS:C0243095
27392483	2034	2052	multi-drug therapy	T058	UMLS:C0013216
27392483	2085	2099	drug-resistant	T038	UMLS:C0013203
27392483	2100	2103	HCV	T005	UMLS:C0220847
27392483	2124	2136	side effects	T038	UMLS:C0041755